Merck (MRK)
Develops oncology medicines, vaccines, cardiopulmonary therapies, and animal-health products worldwide.
Something off on this page? Send us feedback.
Sells prescription medicines, biologic therapies, human vaccines, and animal-health products worldwide, with revenue concentrated in Keytruda oncology and the United States. Pharmaceutical and Animal Health are the reportable segments; Gardasil, Winrevair, Ohtuvayre, and veterinary medicines broaden the portfolio while patent, regulatory, pricing, and reimbursement systems shape demand.
Develops and commercializes prescription medicines, biologic therapies, and vaccines across oncology, cardiometabolic and respiratory disease, infectious disease, hospital care, and other therapeutic areas. Keytruda anchors oncology; vaccines include Gardasil and Gardasil 9, while Winrevair and Ohtuvayre extend the cardiopulmonary portfolio. A separate Animal Health segment supplies medicines, vaccines, and health-management products for livestock and companion animals.
Operates globally as MSD outside the United States and Canada, with the United States contributing most sales. Research, clinical development, regulatory execution, manufacturing, and global commercialization support new indications and launches, while acquisitions and alliances broaden the portfolio. Keytruda generates nearly half of sales, leaving results dependent on its demand, patent protection, and eventual biosimilar competition; pricing and reimbursement rules also shape the pharmaceuticals business.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 11, 2026 | Berenberg Bank | Target | Target: $90 | Target: $137 |
| Sep 10, 2026 | HSBC | Reiterate | Rating: —Target: $150 | Target: $172 |
| Sep 9, 2026 | Leerink Partners | Reiterate | Rating: —Target: $110 | Target: $161 |
| Sep 8, 2026 | Guggenheim | Reiterate | Rating: —Target: $146 | Target: $170 |
| Sep 4, 2026 | Wells Fargo | Reiterate | Rating: —Target: $150 | Target: $170 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.14B · Total debt $53.91B · Total assets $129.80B · Shareholders' equity $41.93B
- Revenue
- $16.61B
- Operating income
- −$683.0M
- Net income
- −$1.34B
HistoryDividendAnnual yield
| Institutions | 82.41% | 2.03B shares | |
|---|---|---|---|
| 3,945 holders · as of Jun 30, 2026 | |||
| Insiders | 0.04% | 1.03M shares | |
| 17 holders · as of Sep 1, 2026 | |||
| Other | 17.55% | 432.91M shares | |
| remainder | |||
2.47B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.20% | 227.00M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.54% | 161.32M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.88% | 120.41M | as of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 3.50% | 86.25M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 2.75% | 67.74M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Chirfi Guindo | officer: EVP, Access, Policy & Comms | −10,000 | $135.00 |
| Aug 12, 2026 | Jennifer Zachary | officer: EVP, General Counsel | −80,315 | $133.46 |
| Aug 12, 2026 | Richard R. DeLuca | officer: EVP&Pres, Merck Animal Heallth | −11,699 | $131.63 |
| Aug 11, 2026 | Richard R. DeLuca | officer: EVP&Pres, Merck Animal Heallth | −12,837 | $131.76 |
| Aug 10, 2026 | Richard R. DeLuca | officer: EVP&Pres, Merck Animal Heallth | −20,784 | $130.43 |
- Bristol-Myers Squibb
Closest PD-1 rival: Opdivo and Opdivo+Yervoy dual checkpoint, 10+ cancer types.
- AstraZeneca (ADR)
Oncology rival: Imfinzi PD-L1, Enhertu ADC, Tagrisso EGFR, Lynparza co-promo.
- Pfizer
Cross-segment rival: Prevnar pneumococcal vaccines and growing PD-1 pipeline.
- Johnson & Johnson
Hematology leader with Darzalex ($11.7B); also rivals in prostate and NSCLC.
- Zoetis
Largest animal health company; head-to-head in parasiticides and livestock.
- GSK (ADR)
HPV rival (Cervarix) internationally and PD-1 oncology challenger via Jemperli.
- Elanco Animal Health
#4 animal health; companion and livestock competitor after aqua divestiture.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Merck | $149.18 | −0.21% | $369.24B | 119.6 | 17.3 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $62.54 | −0.14% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| AstraZeneca (ADR) | $167.86 | −0.14% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Pfizer | $27.66 | −0.29% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Johnson & Johnson | $265.59 | −1.44% | $649.40B | 31.2 | 22.4 | 6.6 | +6.6% |
| Zoetis | $71.63 | +0.41% | $29.90B | 11.8 | 11.5 | 3.1 | +0.3% |
| GSK (ADR) | $50.55 | −1.04% | $102.34B | 16.1 | 9.2 | 2.3 | +5.3% |
| Elanco Animal Health | $22.67 | +1.05% | $11.20B | — | 19.1 | 2.2 | +10.2% |
| Median | 20.7 | 11.5 | 2.6 | +5.7% |